UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 57

Sortiert nach

High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types

Annals of oncology, 2021-05, Vol.32 (5), p.661-672

2021

Link zum Volltext

Verfügbarkeit prüfen

International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment

Annals of oncology, 2011-03, Vol.22 (3), p.515-523

2011

Link zum Volltext

Verfügbarkeit prüfen

Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor- and HER2-defined subtypes

Annals of oncology, 2014-02, Vol.25 (2), p.384-391

2014

Link zum Volltext

Verfügbarkeit prüfen

Impact of Statin Use on Outcomes in Triple-Negative Breast Cancer

International journal of radiation oncology, biology, physics, 2016-10, Vol.96 (2), p.E48-E48

2016

Link zum Volltext

Verfügbarkeit prüfen

Lack of Breastfeeding History in Parous Women With Inflammatory Breast Cancer Predicts Locoregional Recurrence and Distant Metastasis

International journal of radiation oncology, biology, physics, 2015-11, Vol.93 (3), p.E8-E8

2015

Link zum Volltext

Verfügbarkeit prüfen

Medical Oncology Training Programs in the United States

Annals of oncology, 2012-10, Vol.23, p.xi52

Ueno, N.T.

2012

Link zum Volltext

Verfügbarkeit prüfen

Molecular Changes and Targeted Therapy in Inflammatory Breast Cancer

Annals of oncology, 2012-10, Vol.23, p.xi17

Ueno, N.T.

2012

Link zum Volltext

Verfügbarkeit prüfen

Revisiting the definition of estrogen receptor positivity in HER2-negative primary breast cancer

Annals of oncology, 2017-10, Vol.28 (10), p.2420-2428

2017

Link zum Volltext

Verfügbarkeit prüfen

Comprehensive Post-mastectomy Radiation Therapy (PMRT) in Inflammatory Breast Cancer (IBC) Patients with Limited M1 Disease

International journal of radiation oncology, biology, physics, 2011, Vol.81 (2), p.S237-S238

2011

Link zum Volltext

Verfügbarkeit prüfen

Pretreatment Staging PET/CT in Patients with Inflammatory Breast Cancer Influences Radiation Treatment Field Designs

International journal of radiation oncology, biology, physics, 2011, Vol.81 (2), p.S233-S233

2011

Link zum Volltext

Verfügbarkeit prüfen

Medical Oncology Training Programs At the University of Texas MD Anderson Cancer Center Need for Clinical Cancer Biologists to Advance the Field of Medical Oncology

Annals of oncology, 2013-11, Vol.24, p.ix10

Ueno, N.T.

2013

Link zum Volltext

Verfügbarkeit prüfen

27P The biological characteristics of HER2-low in TNBC using mRNA profiling and molecular subtypes

Annals of oncology, 2023-11, Vol.34, p.S1477

2023

Link zum Volltext

Verfügbarkeit prüfen

Triple-Negative/Basal Subtype Predicts Poor Overall Survival and High Locoregional Relapse in Inflammatory Breast Cancer

International journal of radiation oncology, biology, physics, 2010, Vol.78 (3), p.S98-S98

2010

Link zum Volltext

Verfügbarkeit prüfen

Predictors of Overall Survival among Hormone Receptor Positive Patients with Oligometastatic Breast Cancer

International journal of radiation oncology, biology, physics, 2020-11, Vol.108 (3), p.e25-e25

2020

Link zum Volltext

Verfügbarkeit prüfen

689P DB-1305 (a Trop-2 targeted antibody-drug-conjugate [ADC]) in patients (pts) with advanced solid tumors: Preliminary clinical results from the phase (Ph) I/IIa study

Annals of oncology, 2023-10, Vol.34, p.S480-S480

2023

Link zum Volltext

Verfügbarkeit prüfen

Validation of cancer-type-dependent benefit from immune checkpoint blockade in TMB-H tumors identified by the FoundationOne CDx assay

Annals of oncology, 2022-11, Vol.33 (11), p.1204-1206

2022

Link zum Volltext

Verfügbarkeit prüfen

217O Patient-reported outcomes (PROs) from DESTINY-Breast04, a randomized phase III study of trastuzumab deruxtecan (T-DXd) vs treatment of physician's choice (TPC) in patients (pts) with HER2-low metastatic breast cancer (MBC)

Annals of oncology, 2022-09, Vol.33, p.S632-S633

2022

Link zum Volltext

Verfügbarkeit prüfen

Circulating tumor cells in immunohistochemical subtypes of metastatic breast cancer: lack of prediction in HER2-positive disease treated with targeted therapy

Annals of oncology, 2012-05, Vol.23 (5), p.1144-1150

2012

Link zum Volltext

Verfügbarkeit prüfen

Gene expression profiles of inflammatory breast cancer: correlation with response to neoadjuvant chemotherapy and metastasis-free survival

Annals of oncology, 2014-02, Vol.25 (2), p.358-365

2014

Link zum Volltext

Verfügbarkeit prüfen

376O Trastuzumab deruxtecan (T-DXd) versus treatment of physician’s choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Updated survival results of the randomized, phase III DESTINY-Breast04 study

Annals of oncology, 2023-10, Vol.34, p.S334-S335

2023

Link zum Volltext

Verfügbarkeit prüfen

21 - Novel combination of AR inhibitor and CDK4/6 inhibitor, MEK inhibitor in non-HR positive breast cancers

European journal of cancer (1990), 2018-04, Vol.92, p.S14-S15

2018

Link zum Volltext

Verfügbarkeit prüfen

Novel combination of AR inhibitor and CDK4/6 inhibitor, MEK inhibitor in non-HR positive breast cancers

European journal of cancer (1990), 2018-04, Vol.92, p.S14-S15

2018

Link zum Volltext

Verfügbarkeit prüfen

10P Prediction of the 21-gene recurrence score by a non-genomic approach in stage I estrogen receptor-positive, HER2-negative breast cancer

Annals of oncology, 2020-05, Vol.31, p.S19-S20

2020

Link zum Volltext

Verfügbarkeit prüfen

Reply to: ‘Real-world prevalence across 159 872 patients with cancer supports the clinical utility of TMB-H to define metastatic solid tumors for treatment with pembrolizumab.’ by D. Fabrizio et al

Annals of oncology, 2021-09, Vol.32 (9), p.1194-1197

2021

Link zum Volltext

Verfügbarkeit prüfen

A seven-gene signature can predict distant recurrence in patients with triple-negative breast cancers who receive adjuvant chemotherapy following surgery: Park YH, Jung HH, Do I-G, et al (Sungkyunkwan Univ School of Medicine, Seoul, Korea; et al) Int J Cancer 136:1976-1984, 2015

Breast diseases, 2015, Vol.26 (3), p.251-252

2015

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 57

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(54)
Mit Volltextzugriff
(45)

Publikationsform

Artikel
(57)

Sprache

Englisch
(57)
Japanisch
(5)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(21)
Science & Technology
(21)
Oncology
(19)
Humans
(17)
Female
(15)
Biological And Medical Sciences
(14)
Medical Sciences
(13)
Middle Aged
(13)
Adult
(11)
Tumors
(11)
Gynecology. Andrology. Obstetrics
(10)
Mammary Gland Diseases
(10)
Antineoplastic Agents
(9)
Pharmacology. Drug Treatments
(9)
Aged
(6)
Breast Cancer
(6)
Breast Neoplasms - Therapy
(6)
Hematology, Oncology And Palliative Medicine
(6)
Prognosis
(6)
Retrospective Studies
(6)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types

International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment

Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor- and HER2-defined subtypes

Impact of Statin Use on Outcomes in Triple-Negative Breast Cancer

Lack of Breastfeeding History in Parous Women With Inflammatory Breast Cancer Predicts Locoregional Recurrence and Distant Metastasis

Medical Oncology Training Programs in the United States

Molecular Changes and Targeted Therapy in Inflammatory Breast Cancer

Revisiting the definition of estrogen receptor positivity in HER2-negative primary breast cancer

Comprehensive Post-mastectomy Radiation Therapy (PMRT) in Inflammatory Breast Cancer (IBC) Patients with Limited M1 Disease

Pretreatment Staging PET/CT in Patients with Inflammatory Breast Cancer Influences Radiation Treatment Field Designs

Medical Oncology Training Programs At the University of Texas MD Anderson Cancer Center Need for Clinical Cancer Biologists to Advance the Field of Medical Oncology

27P The biological characteristics of HER2-low in TNBC using mRNA profiling and molecular subtypes

Triple-Negative/Basal Subtype Predicts Poor Overall Survival and High Locoregional Relapse in Inflammatory Breast Cancer

Predictors of Overall Survival among Hormone Receptor Positive Patients with Oligometastatic Breast Cancer

689P DB-1305 (a Trop-2 targeted antibody-drug-conjugate [ADC]) in patients (pts) with advanced solid tumors: Preliminary clinical results from the phase (Ph) I/IIa study

Validation of cancer-type-dependent benefit from immune checkpoint blockade in TMB-H tumors identified by the FoundationOne CDx assay

217O Patient-reported outcomes (PROs) from DESTINY-Breast04, a randomized phase III study of trastuzumab deruxtecan (T-DXd) vs treatment of physician's choice (TPC) in patients (pts) with HER2-low metastatic breast cancer (MBC)

Circulating tumor cells in immunohistochemical subtypes of metastatic breast cancer: lack of prediction in HER2-positive disease treated with targeted therapy

Gene expression profiles of inflammatory breast cancer: correlation with response to neoadjuvant chemotherapy and metastasis-free survival

376O Trastuzumab deruxtecan (T-DXd) versus treatment of physician’s choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Updated survival results of the randomized, phase III DESTINY-Breast04 study

21 - Novel combination of AR inhibitor and CDK4/6 inhibitor, MEK inhibitor in non-HR positive breast cancers

Novel combination of AR inhibitor and CDK4/6 inhibitor, MEK inhibitor in non-HR positive breast cancers

10P Prediction of the 21-gene recurrence score by a non-genomic approach in stage I estrogen receptor-positive, HER2-negative breast cancer

Reply to: ‘Real-world prevalence across 159 872 patients with cancer supports the clinical utility of TMB-H to define metastatic solid tumors for treatment with pembrolizumab.’ by D. Fabrizio et al

A seven-gene signature can predict distant recurrence in patients with triple-negative breast cancers who receive adjuvant chemotherapy following surgery: Park YH, Jung HH, Do I-G, et al (Sungkyunkwan Univ School of Medicine, Seoul, Korea; et al) Int J Cancer 136:1976-1984, 2015

Suchergebnisse filtern